Ever since Amarin's (Nasdaq: AMRN ) new drug Vascepa, which lowers triglyceride levels, was approved in July, the biotech space has been rife with talk of a buyout. It has been previously reported that AstraZeneca (NYSE: AZN ) might be considering this purchase, but now an unexpected new company has stepped into the story.
In this video, Motley Fool health care analyst Max Macaluso discusses Teva Pharmaceutical's (NYSE: TEVA ) possible interest in Amarin and whether this drugmaker would actually be a better match than AstraZeneca.
The biotech space can make or break investors over-night, so the success of Amarin's new triglyceride lowering drug is key to the company's future success or failure. Many are optimistic about the drug's success, but the drama surrounding a potential buyout could mean everything for this stock's story. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.